Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $385.0 million.

  • Prime Medicine's Liabilities and Shareholders Equity rose 1569.43% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1748.79%. This contributed to the annual value of $297.5 million for FY2024, which is 5347.25% up from last year.
  • Prime Medicine's Liabilities and Shareholders Equity amounted to $385.0 million in Q3 2025, which was up 1569.43% from $279.0 million recorded in Q2 2025.
  • Prime Medicine's 5-year Liabilities and Shareholders Equity high stood at $385.0 million for Q3 2025, and its period low was $193.9 million during Q4 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $299.7 million (2021), whereas its average is $293.0 million.
  • In the last 5 years, Prime Medicine's Liabilities and Shareholders Equity crashed by 4619.94% in 2023 and then surged by 5347.25% in 2024.
  • Prime Medicine's Liabilities and Shareholders Equity (Quarter) stood at $301.9 million in 2021, then grew by 19.37% to $360.3 million in 2022, then tumbled by 46.2% to $193.9 million in 2023, then skyrocketed by 53.47% to $297.5 million in 2024, then increased by 29.41% to $385.0 million in 2025.
  • Its last three reported values are $385.0 million in Q3 2025, $279.0 million for Q2 2025, and $328.2 million during Q1 2025.